Nigeria, Barbados Seal $32m Pharmaceutical Deal to Produce 12 Million IV Fluid Units Annually by 2029

Nigeria and Barbados have taken a significant step towards expanding pharmaceutical manufacturing cooperation between Africa and the Caribbean following agreements to establish a US$32 million intravenous (IV) fluids manufacturing facility in Barbados, with an annual production target of 12 million units by 2029.

The proposed investment, which brings together Nigerian pharmaceutical expertise, Barbadian industrial ambitions and financing support from the African Export-Import Bank (Afreximbank), is expected to strengthen access to essential medical supplies, reduce dependence on imported pharmaceutical products and create new opportunities for cross-continental trade.

The agreements advancing the project were signed on November 3, 2026, on the sidelines of the Commonwealth Heads of Government Meeting (CHOGM) and Commonwealth Business Forum in Antigua and Barbuda. The arrangement involves Nigerian pharmaceutical manufacturer AMA Medical Manufacturing and Barbados Pharmaceutical Inc. (BPI), alongside a separate project preparation facility term sheet between AMA and Afreximbank.

The manufacturing plant is earmarked for the Grantley Adams Industrial Estate in Christ Church, Barbados. Under the proposed joint venture arrangement, AMA Medical Manufacturing will take responsibility for the facility’s design, construction and operations, while BPI will facilitate access to land, regulatory coordination, government engagement and entry into regional markets.

The facility will deploy advanced aseptic form-fill-seal technology, a specialised manufacturing process designed to maintain sterility and improve production efficiency in pharmaceutical manufacturing. Its initial product focus will be intravenous fluids, which are widely used in hospitals for hydration, medication delivery and the management of patients requiring fluid replacement.

Afreximbank is expected to play a central role in developing the project’s financing structure. Its initial project preparation support will cover feasibility studies and technical, commercial and financial assessments, while the proposed broader financing package could include senior debt, working capital and risk-bearing instruments. However, the full US$32 million investment has not yet been secured, and the project must progress through financing negotiations, regulatory approvals and construction arrangements before implementation.

The proposed investment is also expected to generate substantial employment opportunities in Barbados. Project projections published on the Commonwealth Investment Platform indicate that the facility could create between 147 and 214 direct jobs, alongside approximately 100 additional indirect or residual employment opportunities. These are expected to include specialised positions in pharmaceutical production, sterile manufacturing, quality assurance and technical operations.

Beyond meeting domestic demand, the manufacturing plant is designed to serve the wider Caribbean Community (CARICOM), Latin America and other export destinations. Regional demand for core intravenous products is estimated at more than US$85 million annually, while the Caribbean currently relies heavily on imported supplies, exposing healthcare providers to international shipping delays and supply-chain disruptions.

The partnership builds on an existing commercial relationship between the two countries. AMA Medical Manufacturing delivered its first consignment of intravenous fluids to Barbados in March 2026, while further shipments have been planned for Antigua and Barbuda, the British Virgin Islands and Saint Lucia. The companies are also exploring opportunities to facilitate the entry of Barbadian medical technology into Nigeria, including products developed in collaboration with Barbados-based medical technology company Lenstec.

The pharmaceutical initiative also builds on a broader Nigeria-Barbados cooperation framework established in November 2025, when Barbados Pharmaceutical Inc. and Nigeria’s Presidential Initiative for Unlocking the Healthcare Value Chain signed a memorandum of understanding in Abuja. The agreement provides for collaboration in pharmaceutical manufacturing, workforce development, regulatory cooperation, clinical trials, financing and access to markets across Africa, the Caribbean and Latin America.

Nigeria’s Secretary to the Government of the Federation, Senator George Akume, who represented the Federal Government during the latest engagements, described the partnership as an opportunity to expand industrial cooperation, facilitate technology transfer and strengthen healthcare production through South-South collaboration. Barbados Prime Minister Mia Amor Mottley has similarly championed the development as part of efforts to build domestic pharmaceutical capacity and improve the region’s healthcare security.

The World Trade Organisation Director-General, Dr Ngozi Okonjo-Iweala, also welcomed the initiative, describing it as an example of how international trade and investment can help diversify the production of essential medical supplies. The partnership is expected to demonstrate how African manufacturing capabilities can be connected with Caribbean investment and regional markets to develop more resilient pharmaceutical supply chains.

With feasibility assessments, financing arrangements, regulatory processes and construction planning expected to determine the next phase of implementation, the partners are targeting 2029 for the commencement of commercial production. If delivered as planned, the facility will establish a new pharmaceutical manufacturing link between Nigeria and Barbados, with the potential to expand essential medicine production, create skilled employment and open additional trade opportunities across Africa and the Caribbean.